CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Cancer drug trial halted early after only 3 patients enrolled
Disease control TerminatedThis study tested a drug called tislelizumab against standard chemotherapy for people with classical Hodgkin lymphoma that came back or didn't respond to prior treatments. Only 3 people took part before the study was stopped early. The goal was to see if tislelizumab could slow t…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 16, 2026 22:37 UTC
-
New lymphoma drug trial halted early after only 9 patients
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017 in people with CD30-positive Hodgkin or non-Hodgkin lymphoma that had returned or stopped responding to other treatments. The goal was to check safety and find the right dose. Only 9 people took part before the study was sto…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 16, 2026 22:34 UTC
-
New cancer drug combo tested in early trial
Disease control TerminatedThis early-phase study tested a new drug, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 09, 2026 12:09 UTC